CJ Bioscience, Inc. (KOSDAQ:311690)

Marinus Pharmaceuticals Statistics

Total Valuation

CJ Bioscience has a market cap or net worth of KRW 126.08 billion. The enterprise value is 70.10 billion.

Market Cap	126.08B
Enterprise Value	70.10B

Important Dates

The next estimated earnings date is Thursday, August 14, 2025.

Earnings Date	Aug 14, 2025
Ex-Dividend Date	n/a

Share Statistics

CJ Bioscience has 13.07 million shares outstanding. The number of shares has increased by 30.04% in one year.

Current Share Class	13.07M
Shares Outstanding	13.07M
Shares Change (YoY)	+30.04%
Shares Change (QoQ)	+33.86%
Owned by Insiders (%)	3.54%
Owned by Institutions (%)	0.11%
Float	4.51M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	37.36
PB Ratio	1.76
P/TBV Ratio	2.13
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-2.22
EV / Sales	20.77
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.37

Financial Position

The company has a current ratio of 4.89, with a Debt / Equity ratio of 0.13.

Current Ratio	4.89
Quick Ratio	4.82
Debt / Equity	0.13
Debt / EBITDA	n/a
Debt / FCF	-0.31
Interest Coverage	-56.65

Financial Efficiency

Return on equity (ROE) is -46.60% and return on invested capital (ROIC) is -26.95%.

Return on Equity (ROE)	-46.60%
Return on Assets (ROA)	-24.21%
Return on Invested Capital (ROIC)	-26.95%
Return on Capital Employed (ROCE)	-44.09%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.04
Inventory Turnover	14.87

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -23.93% in the last 52 weeks. The beta is 0.69, so CJ Bioscience's price volatility has been lower than the market average.

Beta (5Y)	0.69
52-Week Price Change	-23.93%
50-Day Moving Average	9,839.40
200-Day Moving Average	10,403.00
Relative Strength Index (RSI)	49.21
Average Volume (20 Days)	107,678

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, CJ Bioscience had revenue of KRW 3.38 billion and -31.59 billion in losses. Loss per share was -3,078.78.

Revenue	3.38B
Gross Profit	270.65M
Operating Income	-33.03B
Pretax Income	-31.59B
Net Income	-31.59B
EBITDA	-28.79B
EBIT	-33.03B
Loss Per Share	-3,078.78

Balance Sheet

The company has 65.02 billion in cash and 9.03 billion in debt, giving a net cash position of 55.98 billion or 4,284.87 per share.

Cash & Cash Equivalents	65.02B
Total Debt	9.03B
Net Cash	55.98B
Net Cash Per Share	4,284.87
Equity (Book Value)	71.63B
Book Value Per Share	5,482.15
Working Capital	53.20B

Cash Flow

In the last 12 months, operating cash flow was -29.21 billion and capital expenditures -377.59 million, giving a free cash flow of -29.59 billion.

Operating Cash Flow	-29.21B
Capital Expenditures	-377.59M
Free Cash Flow	-29.59B
FCF Per Share	-2,264.93

Margins

Gross Margin	8.02%
Operating Margin	-978.69%
Pretax Margin	-936.05%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

CJ Bioscience does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-30.04%
Shareholder Yield	n/a
Earnings Yield	-25.06%
FCF Yield	-23.47%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CJ Bioscience has an Altman Z-Score of 1.79 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.79
Piotroski F-Score	2